Skip Navigation

Ian Copland, PhD

Assistant Professor
Emory University School of Medicine

Dr. Copland has over 15 years of experience in research in both academic and industrial settings, 7 of which he has engaged in research on cellular therapies. Dr. Copland obtained his PhD in 2005 from the University of Toronto and from 2005-2008 conducted a post-doctoral fellowship at McGill University focused on the neovascularization properties of Mesenchymal stromal cells. From 2008-2010, he was the Regenerative Medicine program director at AccelLAB Inc., a contract research organization in Montreal Canada. As the Regenerative Medicine program director at AccelLAB, Dr. Copland facilitated the clinical translation of promising cellular and device platforms for cardiac and orthopedic regenerative medicine. To date, he has over 20 published medline-indexed, peer-reviewed papers and reviews. Of these, 8 are directly related to the usage of cellular therapies.

Research Interests

In August 2010, Dr. Copland was appointed as an Assistant Professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine. His mandate is to identify the molecular mechanisms that regulate the regenerative capacity of stem/progenitor cells. In particular, Dr. Copland is interested in the therapeutic potential of mesenchymal stromal cells (MSCs) for immune disorders, therapeutic angiogenesis and cancer immunotherapy. Besides MSCs, his group is also developing cellular therapies using monocytes, T-cells and dendritic cells, which are intended to be autologous in nature.

Dr. Copland is also the Laboratory Director of the Emory Personalized Immunotherapy Center (EPIC). As the Laboratory Director, he helps direct the strategic planning, development and operational management of this GMP-compliant cell handling facility located within Emory University hospital. Within the next year, his group will be engaging in a Emory-initiated Phase I clinical trial to treat patients with medically refractory inflammatory bowel disease (IBD) using their own MSCs. He is also in the planning stages of a trial involving the use of autologous MSCs to treat graft vs host disease.

In January 2011, Dr. Copland was also appointed a faculty member in the Parker H. Petit Institute for Bioengineering and Bioscience (IBB) at Georgia Tech. Through synergism with people at Georgia Tech, his group is investigating several novel platforms for the expansion and clinical usage of somatic cellular therapies.


View publications on PubMed